# Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)

> **NCT05724329** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 24 (actual)

## Conditions studied

- Head and Neck Squamous Cell Carcinomas

## Interventions

- **DRUG:** Tislelizumab + Dasatinib + Quercetin (neoadjuvant)
- **PROCEDURE:** surgery
- **DRUG:** Tislelizumab + Dasatinib + Quercetin (adjuvant)

## Key facts

- **NCT ID:** NCT05724329
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-02-05
- **Primary completion:** 2024-04-05
- **Final completion:** 2028-08-05
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05724329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05724329, "Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05724329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*